The Complete Guide
Hormone therapy for women: what the evidence actually says
A practical guide for women in perimenopause and menopause who want a clear-eyed look at the benefits, risks, and modern understanding of hormone therapy.
What menopausal hormone therapy actually is
Menopausal hormone therapy — often called HRT (hormone replacement therapy) or MHT (menopausal hormone therapy) — is the use of estrogen and (in women with a uterus) progesterone to address symptoms and health risks associated with declining ovarian hormone production during perimenopause and menopause. It is one of the most effective interventions in medicine for a specific group of women, and one of the most misunderstood.
The modern consensus from the Menopause Society (formerly NAMS) is this: for healthy women under 60 or within 10 years of menopause onset who are experiencing moderate-to-severe symptoms, the benefits of hormone therapy generally outweigh the risks. That sentence would have been considered heresy in the years after the Women's Health Initiative (WHI) study was first reported in 2002. It is now the mainstream position supported by the authoritative clinical societies.
If you were told by a doctor in 2005 that hormone therapy causes cancer and heart attacks, you were told what was believed at the time based on an incomplete reading of the WHI data. The science has evolved substantially. The current recommendations from the Menopause Society are meaningfully different. If you have not had the conversation in a few years, it is worth revisiting.
Why the story changed
The 2002 WHI study reported an increased risk of breast cancer, heart disease, stroke, and blood clots in women taking combined estrogen and progestin. Headlines went global. Hormone therapy prescribing collapsed almost overnight. Millions of women stopped taking hormones they had been benefitting from, and a generation of physicians was trained to be wary of prescribing.
Subsequent re-analyses of the WHI data, plus newer trials like ELITE and KEEPS, told a more nuanced story. The original WHI enrolled older women — most were in their 60s and 70s — and used older formulations. When the data was re-examined by age group and type of therapy, the risk picture changed. For women who start hormone therapy early in the menopause transition (the 'timing hypothesis' window of roughly under 60 or within 10 years of final menstrual period), the cardiovascular risk picture is largely favorable, and the modest absolute increase in breast cancer risk with combined therapy is offset by improvements in bone health, quality of life, and symptom control.
The formulations have also changed. Modern transdermal estradiol (patch, gel, spray) bypasses first-pass liver metabolism and has a better clotting and stroke risk profile than oral conjugated equine estrogens. Micronized progesterone is more commonly used than the older progestins in combination therapy. Related: perimenopause weight loss guide and menopause weight loss guide.
What hormone therapy actually does
- Vasomotor symptoms. Hot flashes and night sweats. HRT is by far the most effective treatment available. Many women report 70-90% reduction in severity within weeks.
- Genitourinary symptoms. Vaginal dryness, painful intercourse, recurrent UTIs. Low-dose vaginal estrogen (a separate formulation from systemic HRT) is extremely effective and has a favorable safety profile even for women who cannot take systemic hormones.
- Sleep. For women whose sleep is disrupted by night sweats, HRT often restores normal sleep. Better sleep reverberates through everything else.
- Bone density. Estrogen protects bone. Early-menopause hormone therapy reduces the rate of osteoporotic fractures, and the Menopause Society lists bone health as one of the primary long-term benefits.
- Mood and cognition. Some women report meaningful improvements in mood, mental clarity, and brain fog, particularly in the perimenopause window.
- Cardiovascular health. For women who start hormone therapy early (the timing hypothesis window), modern evidence suggests a neutral-to-favorable cardiovascular picture, particularly with transdermal estradiol.
What HRT does not do: stop the aging process, restore fertility, or cure unrelated health problems. It restores the hormonal environment that used to be there and addresses the specific symptoms of its absence.
Who is appropriate (and who is not)
The Menopause Society's 2022 position statement suggests that healthy women under 60 or within 10 years of menopause onset, with moderate-to-severe symptoms, are generally good candidates for hormone therapy. That is a broad group. Outside that window, the conversation becomes more individualized and the evidence is less favorable.
Contraindications — situations where hormone therapy is generally not used — include:
- Current or prior hormone-sensitive cancer (breast, endometrial).
- Unexplained vaginal bleeding not yet evaluated.
- Active or recent deep vein thrombosis, pulmonary embolism, stroke, or heart attack.
- Active liver disease.
- Pregnancy.
- Known or suspected hypersensitivity to hormone therapy products.
A licensed physician evaluates your full history and decides whether hormone therapy is appropriate. Many women who worry they do not qualify — because of a family history of breast cancer, for example — actually do qualify after a careful review. The conversation is worth having.
Delivery methods and what they mean
- Transdermal patch, gel, spray. Estrogen absorbed through the skin bypasses first-pass liver metabolism. Lower risk of blood clots compared to oral. The preferred route in modern practice for many women.
- Oral tablets. Convenient but raises clotting factors more than transdermal. Still appropriate for many women.
- Vaginal estrogen (cream, tablet, ring). Very low systemic absorption. Used for genitourinary symptoms. Safe for most women including many who cannot take systemic hormones.
- Pellets. Implanted under the skin. Convenient but dosing is inflexible and serum levels can be unpredictable. A minority choice in modern practice.
- Micronized oral progesterone. Taken nightly with combined hormone therapy if you still have a uterus (to protect the endometrium from unopposed estrogen). Has a mild sedating effect that can be helpful for sleep.
How to get started
If you are in perimenopause or menopause and dealing with symptoms that affect your sleep, mood, work, or relationships, complete your assessment. A licensed Puri-affiliated physician will review your history, order any necessary labs, and decide whether hormone therapy is appropriate. A prescription is not guaranteed.
